CRBU — Caribou Biosciences, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1619856 ·
Last close
$0.34
Market Cap
$36.81M
52W High
$2.49
52W Low
$0.32
ADV30
4,538,916
Next earnings
2026-11-11
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 1,607,000 | — | -27,642,000 | -26,612,000 | 123,026,000 | 26,057,000 | 46,393,000 |
| Jun 2026 | 1,499,000 | — | -25,339,000 | -24,282,000 | 142,774,000 | 26,194,000 | 44,672,000 |
| Mar 2026 | 2,397,000 | — | -26,280,000 | -25,085,000 | 148,998,000 | 12,057,000 | 46,980,000 |
| Dec 2025 | 3,941,000 | — | -28,453,000 | -26,488,000 | 175,367,000 | 12,360,000 | 53,192,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-95,780,000
Investing CF
$71,748,000
Financing CF
$24,979,000
CapEx
$-606,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.08
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-645,882,000
Inventory
—
Receivables
$1,941,000
ST Investments
$86,120,000
EBIT TTM
$-109,472,000
Pretax Income TTM
$-103,953,000
Interest Exp TTM
—
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$9,444,000
EBITDA
$-102,892,000
Free Cash Flow
$-54,259,752
Enterprise Value
$-19,985,920
Total Cash
$94,800,000
Total Debt
$26,338,000
Shares Out
108,036,729
Trailing EPS
$-1.03
Book Value
$0.71
ROE
-93.8%
ROA
-41.4%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 11,159,000 | -136,194,000 | -148,125,000 | 175,367,000 | 53,192,000 | 122,175,000 | -110,992,000 |
| Dec 2024 | 9,994,000 | -166,616,000 | -149,105,000 | 313,313,000 | 60,362,000 | 252,951,000 | -138,200,000 |
| Dec 2023 | 34,477,000 | -116,059,000 | -102,070,000 | 432,209,000 | 63,808,000 | 368,401,000 | -93,291,000 |
| Dec 2022 | 13,851,000 | -106,399,000 | -99,421,000 | 373,765,000 | 72,894,000 | 300,871,000 | -90,966,000 |
TTM Snapshot
Revenues TTM
$10,035,000
NetIncome TTM
$-103,403,000
OpCashFlow TTM
—
Assets (Latest)
$142,774,000
Forward EPS
$-0.90
Max Pain — expiry 2027-04-16 (volume-derived — Yahoo OI feed degraded)
max pain strike: $0.50 · spot: $0.33 · call volume: 11 · put volume: 1
Expected Move to 2027-04-16:
±$0.25
(76.69%) —
implied range
$0.08 –
$0.58
· ATM straddle on $0.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TIL | Instil Bio, Inc. | $36.62M | $5.40 | — |
| TVGN | Tevogen Inc. | $37.05M | $5.69 | — |
| BKHA | Black Hawk Acquisition Corp | $35.93M | $8.65 | — |
| ELUT | ELUTIA INC. | $37.91M | $0.85 | — |
| KLRS | Kalaris Therapeutics, Inc. | $34.04M | $1.43 | — |
News headlines (Yahoo Finance, 1h cache)
Caribou Biosciences (CRBU) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
2026-11-12 13:55 · Yahoo
Caribou Biosciences (CRBU) Stock Sees Fair Value Cut After Clinical Programs Halted
2026-11-12 06:10 · Yahoo
Caribou Biosciences, Inc. (CRBU) Reports Q3 Loss, Beats Revenue Estimates
2026-11-06 00:00 · Yahoo
Caribou Biosciences Reports Third Quarter 2026 Financial Results
2026-11-05 21:05 · Yahoo
Caribou Biosciences, Inc. (CRBU) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
2026-11-04 14:00 · Yahoo
Caribou Biosciences Announces Presentations at the 2026 American Society of Hematology (ASH) Annual Meeting
2026-11-04 14:00 · Yahoo
Caribou Biosciences (CRBU) Stock Fair Value Falls After Clinical Programs Are Halted
2026-10-28 06:16 · Yahoo
In the hunt for reverse merger targets, Caribou could be prized game
2026-10-08 15:23 · Yahoo
Caribou to halt CAR-T work, lay off staff amid ‘challenging’ funding climate
2026-10-07 15:37 · Yahoo
CRBU Stock Crashes 35% Premarket — RBC Slashes Target By 90% After Caribou Scraps CAR-T Programs
2026-10-07 10:49 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.